Moderna on Thursday said its COVID-19 vaccine offers better protection against so-called breakthrough cases than its rival Pfizer’s jab, but also said that more cases of heart inflammation have been seen in people who received its shot.
“A small increase in cases of myocarditis is seen with mRNA-1273 compared to BNT162b2 in males 12–29 years of age,” a slide shown during a press briefing held by the company stated.
